EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 430 (2023) E3S Web Conf., 430 (2023) 01279 References
Open Access
Issue
E3S Web Conf.
Volume 430, 2023
15th International Conference on Materials Processing and Characterization (ICMPC 2023)
Article Number 01279
Number of page(s) 10
DOI https://doi.org/10.1051/e3sconf/202343001279
Published online 06 October 2023
  1. A. M. Ahmed, “History of diabetes mellitus.,” Saudi Med. J., vol. 23, no. 4, pp. 373–378, Apr. 2002. [Google Scholar]
  2. P. Zimmet, K. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. [CrossRef] [PubMed] [Google Scholar]
  3. C. M. Ripsin, H. Kang, and R. J. Urban, “Management of blood glucose in type 2 diabetes mellitus,” Am. Fam. Physician, vol. 79, no. 1, pp. 29–36, 2009. [Google Scholar]
  4. M. Azevedo and S. Alla, “Diabetes in sub-saharan Africa: kenya, mali, mozambique, Nigeria, South Africa and zambia,” Int. J. Diabetes Dev. Ctries., vol. 28, no. 4, p. 101, 2008. [CrossRef] [PubMed] [Google Scholar]
  5. A. J. Garber et al., “American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement,” Endocr. Pract., vol. 19, pp. 1–48, 2013. [CrossRef] [Google Scholar]
  6. B. Nightingale, “A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure.,” Cardiol. Res., vol. 12, no. 2, pp. 60–66, Apr. 2021, doi: 10.14740/cr1221. [CrossRef] [PubMed] [Google Scholar]
  7. M. Christensen, F. K. Knop, J. J. Holst, and T. Vilsboll, “Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.,” IDrugs Investig. drugs J., vol. 12, no. 8, pp. 503–513, 2009. [Google Scholar]
  8. R. A. DeFronzo, R. C. Bonadonna, and E. Ferrannini, “Pathogenesis of NIDDM: a balanced overview,” Diabetes Care, vol. 15, no. 3, pp. 318–368, 1992. [CrossRef] [PubMed] [Google Scholar]
  9. “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.,” Lancet (London, England), vol. 352, no. 9131, pp. 837–853, Sep. 1998. [CrossRef] [PubMed] [Google Scholar]
  10. A. S. Krolewski, A. Czyzyk, D. Janeczko, and J. Kopczyński, “Mortality from cardiovascular diseases among diabetics,” Diabetologia, vol. 13, no. 4, pp. 345–350, 1977. [CrossRef] [PubMed] [Google Scholar]
  11. S. Hummasti and G. S. Hotamisligil, “Endoplasmic reticulum stress and inflammation in obesity and diabetes,” Circ. Res., vol. 107, no. 5, pp. 579–591, 2010. [CrossRef] [PubMed] [Google Scholar]
  12. D. Yach, C. Hawkes, C. L. Gould, and K. J. Hofman, “The global burden of chronic diseases: overcoming impediments to prevention and control,” Jama, vol. 291, no. 21, pp. 2616–2622, 2004. [CrossRef] [PubMed] [Google Scholar]
  13. A. J. Scheen, “Drug interactions of clinical importance with antihyperglycaemic agents,” Drug Saf., vol. 28, no. 7, pp. 601–631, 2005. [CrossRef] [Google Scholar]
  14. N. Chiniwala and S. Jabbour, “Management of diabetes mellitus in the elderly,” Curr. Opin. Endocrinol. iabetes Obes., vol. 18, no. 2, pp. 148–152, 2011. [CrossRef] [PubMed] [Google Scholar]
  15. D. K. Tanwar, A. Ratan, and M. S. Gill, “A facile synthesis of sulfonylureas via water assisted preparation of carbamates,” Org. Biomol. Chem., vol. 15, no. 23, pp. 4992–4999, 2017. [CrossRef] [PubMed] [Google Scholar]
  16. C. A. Collier, C. R. Bruce, A. C. Smith, G. Lopaschuk, and D. J. Dyck, “Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle,” Am. J. Physiol. Metab., vol. 291, no. 1, pp. E182–E189, 2006. [Google Scholar]
  17. G. G. Graham et al., “Clinical pharmacokinetics of metformin,” Clin. Pharmacokinet., vol. 50, no. 2, pp. 81–98, 2011. [CrossRef] [PubMed] [Google Scholar]
  18. E. A. Werner and J. Bell, “CCXIV.—The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively,” J. Chem. Soc. Trans., vol. 121, pp. 1790–1794, 1922. [CrossRef] [Google Scholar]
  19. D. Care, “In the same tables, the sentence ‘The diagnosis of GDM is made when the plasma glucose level measured 3 h after the test is≥ 140 mg/dL (7.8 mmol/L)’ is incorrect. The corrected sentence is as follows:”the diagnosis of GDM is made when at least two of the following four plasma glucose levels (measured fasting, 1 h, 2 h, 3 h after the OGTT) are met or exceeded,” Diabetes Care, vol. 37, p. 887, 2014. [Google Scholar]
  20. M. R. Burge and D. S. Schade, “Insulins,” Endocrinol. Metab. Clin. North Am., vol. 26, no. 3, pp. 575–598, 1997. [CrossRef] [Google Scholar]
  21. C. G. Cameron and H. A. Bennett, “Cost-effectiveness of insulin analogues for diabetes mellitus,” Cmaj, vol. 180, no. 4, pp. 400–407, 2009. [CrossRef] [PubMed] [Google Scholar]
  22. C. J. Bailey and C. Day, “Metformin: its botanical background,” Pract. diabetes Int., vol. 21, no. 3, pp. 115–117, 2004. [CrossRef] [Google Scholar]
  23. P. Fouqueray et al., “The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy,” Diabetes Care, vol. 36, no. 3, pp. 565–568, 2013. [CrossRef] [PubMed] [Google Scholar]
  24. H. Yaribeygi, M. Maleki, T. Sathyapalan, T. Jamialahmadi, and A. Sahebkar, “Molecular mechanisms by which imeglimin improves glucose homeostasis,” J. Diabetes Res., vol. 2020, 2020. [Google Scholar]
  25. F. Wagner et al., “Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock,” Crit. , vol. 16, no. 1, pp. 1–189, 2012. [Google Scholar]
  26. D. Detaille et al., “Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration,” Cell death Discov., vol. 2, no. 1, pp. 1–8, 2016. [CrossRef] [Google Scholar]
  27. R. Yendapally et al., “A review of phenformin, metformin, and imeglimin,” Drug Dev. Res., vol. 81, no. 4, pp. 390–401, 2020. [CrossRef] [PubMed] [Google Scholar]
  28. C. Konkwo and R. J. Perry, “Imeglimin: current development and future potential in type 2 diabetes,” Drugs, vol. 81, no. 2, pp. 185–190, 2021. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.